Revolve Wealth Partners LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 4.2% in the 4th quarter, Holdings Channel reports. The fund owned 491 shares of the medical research company’s stock after purchasing an additional 20 shares during the period. Revolve Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $255,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Driehaus Capital Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 75.0% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,524 shares of the medical research company’s stock worth $843,000 after acquiring an additional 653 shares during the period. Quarry LP raised its stake in Thermo Fisher Scientific by 86.2% during the second quarter. Quarry LP now owns 121 shares of the medical research company’s stock worth $67,000 after purchasing an additional 56 shares during the period. EP Wealth Advisors LLC boosted its holdings in shares of Thermo Fisher Scientific by 5.8% in the 2nd quarter. EP Wealth Advisors LLC now owns 14,991 shares of the medical research company’s stock valued at $8,290,000 after purchasing an additional 816 shares during the last quarter. Pathway Financial Advisers LLC increased its holdings in shares of Thermo Fisher Scientific by 2.3% during the 2nd quarter. Pathway Financial Advisers LLC now owns 1,450 shares of the medical research company’s stock worth $783,000 after buying an additional 33 shares during the last quarter. Finally, Advisory Alpha LLC raised its stake in shares of Thermo Fisher Scientific by 34.7% in the 2nd quarter. Advisory Alpha LLC now owns 1,049 shares of the medical research company’s stock valued at $580,000 after acquiring an additional 270 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.
Insider Buying and Selling at Thermo Fisher Scientific
In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the sale, the chief executive officer now directly owns 111,192 shares of the company’s stock, valued at approximately $58,960,669.92. This represents a 8.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 34,850 shares of company stock valued at $19,123,197 in the last 90 days. 0.34% of the stock is currently owned by insiders.
Thermo Fisher Scientific Stock Performance
Thermo Fisher Scientific announced that its board has initiated a stock repurchase program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase up to 2% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company’s board of directors believes its stock is undervalued.
Thermo Fisher Scientific Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were given a dividend of $0.39 per share. The ex-dividend date was Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is presently 9.78%.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the company. Bank of America reduced their price objective on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Bernstein Bank upped their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the stock a “market perform” rating in a research note on Tuesday, October 22nd. StockNews.com upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Finally, Barclays lowered their price objective on shares of Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research note on Wednesday, October 23rd. Four investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and an average target price of $648.95.
Get Our Latest Research Report on Thermo Fisher Scientific
Thermo Fisher Scientific Profile
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Recommended Stories
- Five stocks we like better than Thermo Fisher Scientific
- How to Calculate Inflation Rate
- Survey Reveals: Top 150 Best Coffee Shops for Remote Workers and Business Deals [2025]
- What is diluted earnings per share (Diluted EPS)?
- What Does the Future Hold for Eli Lilly?
- What is the Dogs of the Dow Strategy? Overview and Examples
- Oracle Stock Drops Nearly 14% – Is Now the Time to Buy?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.